Li Sijia, Deng Shuting, Wen Sichun, Peng Siqi, Jiang Nan, Li Bohou, Chen Boxi, Yuan Ye, Wu Qiong, Tao Yiming, Ma Jianchao, Lin Ting, Wen Feng, Li Zhuo, Dai Hao, Huang Renwei, Feng Zhonglin, Li Zhilian, Liu Shuangxin, Xu Lixia
Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
School of Medicine, South China University of Technology, Guangzhou, China.
Case Rep Nephrol Dial. 2024 Mar 22;14(1):42-47. doi: 10.1159/000538033. eCollection 2024 Jan-Dec.
Refractory lupus nephritis (LN) causes kidney disease progression and increases the risk of loss of renal function. Due to the high specificity and few side effects of biological agents, they are recommended for the treatment of systemic lupus erythematosus. There are few data on telitacicept for the treatment of refractory LN.
Here, we report the efficacy and safety of telitacicept in the treatment of refractory LN in a 25-year-old female patient. This patient with refractory lupus developed pneumonia while using multitargeted therapy, and the patient's urine protein was rapidly relieved after telitacicept combination with low-dose mycophenolate mofetil (MMF).
This result suggests that telitacicept has a positive effect on refractory LN with no significant side effects. Further reports and a registry are necessary to confirm that telitacicept with low-dose MMF should be preferred in refractory LN.
难治性狼疮性肾炎（LN）会导致肾脏疾病进展，并增加肾功能丧失的风险。由于生物制剂具有高特异性且副作用少，因此推荐用于治疗系统性红斑狼疮。关于泰它西普治疗难治性LN的数据较少。
在此，我们报告了泰它西普治疗一名25岁女性难治性LN患者的疗效和安全性。该难治性狼疮患者在使用多靶点治疗时发生肺炎，在泰它西普联合低剂量霉酚酸酯（MMF）治疗后，患者尿蛋白迅速缓解。
该结果表明泰它西普对难治性LN有积极作用，且无明显副作用。需要进一步的报告和登记研究来证实，在难治性LN中，应优先选择低剂量MMF联合泰它西普治疗。
